

# STRAGEN

SWISS HEALTH CARE COMPANY 

## CORPORATE BROCHURE

PHARMA




CONSUMER HEALTH

NEW DRUGS

# CONTENT

STRAGEN is a Swiss Health Care company specialized in the development and commercialization of niche Generic and Generic+ pharmaceuticals, innovative consumer health products, and in the early-stage development of new drugs.

CORPORATE

A WORD FROM OUR CEO	4
VISION & VALUES	5
WHO WE ARE	7
WHERE WE ARE	9
WHAT WE DO	10
 PHARMACEUTICALS	12
 CONSUMER HEALTH	22
 NEW DRUG DEVELOPMENT	27
STRAGEN WORLDWIDE OFFICES	32
HEADQUARTERS IN SWITZERLAND	33



STRAGEN,  
SWISS HEALTH CARE  
COMPANY

STRAGEN is a Swiss Health Care company specialized in the development and commercialization of niche Generic and Generic+ pharmaceuticals, innovative consumer health products, and in the early-stage development of new drugs.

Jean-Luc TETARD  
CEO & founder



The world is changing and the Pharma industry has had to adapt to new working conditions and surroundings.

At STRAGEN we understand that business models need to be reinvented to cope with very competitive and fast changing environments. For this reason, our group has decided to take control of its future by diversifying our activity beyond our historical development and licensing out of Generic+ products to the development of consumer health as well as the development up to proof of concept of patented new drugs. A strong emphasis also lies on opening our own affiliates organization around the world to provide Swiss quality products directly under the STRAGEN name.

We trust that this Corporate brochure will translate our entrepreneurial philosophy, which has made the success of our company for the last 30 years, and will continue to lead our group towards a bright future.

STRAGEN is a Swiss Health Care company specialized in the development and commercialization of niche Generic and Generic+ pharmaceuticals, innovative consumer health products, and in the early-stage development of new drugs.

“ Digital communication...  
and expansion of our B2C model  
will be our focus for the years to come. ”



Jan TETARD  
Executive Vice President

The STRAGEN team has recognised the direction in which globalization and digitalization have been steering business worldwide.

Due to these developments, our company has proactively set new communication methods that allow a closer dialogue with our partners and customers. Not only have we created a substantial presence on social media, but we are continuously looking for new platforms on which we can help consumers relationships grow.

Digital communication, community management and expansion of our B2C model will be our focus for the years to come. This will involve everyone in the company and strengthen STRAGEN as a group around the world.

STRAGEN is a Swiss Health Care company specialized in the development and commercialization of niche Generic and Generic+ pharmaceuticals, innovative consumer health products, and in the early-stage development of new drugs.

“ Digital communication...  
and expansion of our B2C model  
will be our focus for the years to come. ”

A close-up photograph of a hand holding a small, white, oval-shaped pill between the thumb and index finger. The background is a soft, out-of-focus light blue and white.

We aspire to continuously expand  
through new developments  
and market opportunities  
providing high-quality,  
innovative health care  
products on a global scale.

In all we do, we strive to be  
innovative, reliable and passionate.

STRAGEN is a Swiss Health Care company specialized in the development and commercialization of niche Generic and Generic+ pharmaceuticals, innovative consumer health products, and in the early-stage development of new drugs.

The entrepreneurial and proactive approach of STRAGEN has enabled the company to develop a wide range of products and become an innovative, reliable, and passionate partner in health care.

### **ENTREPRENEURS**

STRAGEN functions as a team of multi-national health care professionals with the ability to identify and engage in new market opportunities worldwide.

For more than 25 years, our team has been delivering innovative and trusted results while continuously operating under the highest quality standards.

### **HEALTH CARE EXPERTS**

STRAGEN is characterized by the group's long-lived experience in the development of complex health care products, enabled by professionally integrated teams in Development, Regulatory Affairs, Supply Chain, and Quality Assurance, as well as the company's dedicated central management.

### **PARTNERS**

STRAGEN is driven by building strong long-term relationships with industrial partners and customers, a key element in the evolution of STRAGEN.

STRAGEN is a Swiss Health Care company specialized in the development and commercialization of niche Generic and Generic+ pharmaceuticals, innovative consumer health products, and in the early-stage development of new drugs.

The entrepreneurial and proactive approach of STRAGEN has enabled the company to develop a wide range of products and become an innovative, reliable, and passionate partner in health care.




STRAGEN keeps on growing...



STRAGEN is a Swiss Health Care company specialized in the development and commercialization of niche Generic and Generic+ pharmaceuticals, innovative consumer health products, and in the early-stage development of new drugs.

STRAGEN expands its international presence through a network of partners, exclusive distributors, and new affiliate offices.

**10 GLOBAL AFFILIATES**    **B2B PRESENCE IN OVER 60 COUNTRIES**



**HEADQUARTERS IN GENEVA, SWITZERLAND**

STRAGEN is a Swiss Health Care company specialized in the development and commercialization of niche Generic and Generic+ pharmaceuticals, innovative consumer health products, and in the early-stage development of new drugs.

STRAGEN HQ is located in Geneva, Switzerland, and operates as a central platform for the group.

Our organisational structure



STRAGEN is a Swiss Health Care company specialized in the development and commercialization of niche Generic and Generic+ pharmaceuticals, innovative consumer health products, and in the early-stage development of new drugs.

STRAGEN HQ is located in Geneva, Switzerland, and operates as a central platform for the group.

## Our business units



**STRAGEN PHARMA** engages in the development, registration, and supply of a selected range of oral, parenteral, and topical products in a variety of therapeutic areas, such as anti-infectives, cardiology, oncology, oral contraception, etc.



**STRAGEN CONSUMER HEALTH** specializes in the development of innovative products with clinically proven efficacy and safety.













**STRAGEN NEW DRUG DEVELOPMENT** identifies promising patented compounds from biotechnology start-ups as well as academic institutions and develops these into drugs of high therapeutic potential.




# PHARMACEUTICALS

STRAGEN Pharma engages in the development, registration, and supply of Generic drugs of high quality standards.

	<b>ANTI-INFECTIVES</b> _____	14
	<b>ANTI-INFLAMMATORY</b> _____	15
	<b>CARDIOLOGY</b> _____	16
	<b>EPILEPSY</b> _____	17
	<b>DERMATOLOGY</b> _____	18
	<b>HAEMORRHAGE</b> _____	18
	<b>GYNAECOLOGY</b> _____	18
	<b>ONCOLOGY</b> _____	20
	<b>PHLEBOLOGY</b> _____	20
	<b>HAEMATOLOGY</b> _____	21

Generic and Generic<sup>+</sup> drugs mainly focused on injectable anti-infective and oncology products, cardiology and gynaecology.



## ANTI-INFECTIVES

### **CEFEPIME**

Powder for solution for injection or infusion  
Vials 1 g/20 ml, 2 g/50 ml

### **CEFOTAXIME**

Powder for solution for IV injection or infusion  
Vials 500 mg/10 ml, 1 g/10 ml, 2 g/20 ml, 2 g/50 ml

### **CEFTAZIDIME**

Powder for solution for IV/IM injection or infusion  
Vials 250 mg/15 ml, 500 mg/15 ml, 1 g/15 ml, 1 g/50 ml, 2 g/50 ml, 3 g/100 ml

### **CEFTRIAXONE**

Powder for solution for IV/IM injection or infusion  
Vials 500 mg/15 ml, 1 g/15 ml, 1 g/50 ml, 2 g/50 ml, 10 g/100 ml


### **CEFUROXIME**

Powder for solution for IV/IM injection  
Vials 250 mg/15 ml, 750 mg/15 ml, 1.5 g/20 ml

### **CLOXACILLINE**

Powder for solution for IV/IM injection or infusion  
Vials 1 g/20 ml, 2 g/20 ml, 2 g/50 ml, 10 g/100 ml

Generic and Generic<sup>+</sup> drugs mainly focused on injectable anti-infective and oncology products, cardiology and gynaecology.



## ANTI-INFECTIVES

### **ERYTHROMYCINE**

Powder for solution for infusion  
Vial 1 g/30 ml

### **FLUCLOXACILLINE**

Powder for solution for IV/IM injection  
Vials 1 g/20 ml, 2 g/50 ml

### **PIPERACILLINE / TAZOBACTAM**

Powder for solution for infusion  
Vials 2 g/250 mg, 3 g/375 mg, 4 g/500 mg, 12 g/1.5 g, 36 g/4.5 g



## ANTI-INFLAMMATORY

### **DICLOFENAC 1%**

Gel in tube 50 g, 100 g

STRAGEN Pharma engages in the development, registration, and supply of a selected range of oral, parenteral, and topical products in a variety of therapeutic areas, such as anti-infectives, cardiology, oncology, oral contraception, etc.

Generic and Generic+ drugs mainly focused on injectable anti-infective and oncology products, cardiology and gynaecology.



## CARDIOLOGY

### AMIODARONE

Concentrate for solution for injection or infusion  
Ampoules 150 mg/3 ml

### MILRINONE

Concentrate for solution for infusion  
Ampoules 10 mg/10 ml, 20 mg/20 ml

### URAPIDIL

Solution for IV injection / Concentrate for solution for infusion  
Ampoules 25 mg/5 ml, 50 mg/10 ml, 100 mg/20 ml

### URAPIDIL ORAL

Prolonged-release capsules 30 mg, 60 mg, 90 mg

**URAPIDIL ORAL,**  
the 1<sup>st</sup> & only generic on the market





STRAGEN Pharma engages in the development, registration, and supply of a selected range of oral, parenteral, and topical products in a variety of therapeutic areas, such as anti-infectives, cardiology, oncology, oral contraception, etc.

Generic and Generic+ drugs mainly focused on injectable anti-infective and oncology products, cardiology and gynaecology.



## EPILEPSY

### LEVETIRACETAM

Ready-to-use solution for infusion in bag  
500 mg/100 ml, 1000 mg/100 ml, 1500 mg/100 ml



**LEVETIRACETAM,**  
the 1<sup>st</sup> ready-to-use bag

STRAGEN Pharma engages in the development, registration, and supply of a selected range of oral, parenteral, and topical products in a variety of therapeutic areas, such as anti-infectives, cardiology, oncology, oral contraception, etc.

Generic and Generic<sup>+</sup> drugs mainly focused on injectable anti-infective and oncology products, cardiology and gynaecology.



## DERMATOLOGY

### ADAPALENE 0.1%

Cream / gel in tube 30 g, 45 g, 60 g

---



## HAEMORRHAGE

### TRANEXAMIC ACID

Solution for injection  
Ampoules 500 mg/5 ml, 1000 mg/10 ml

---



## GYNAECOLOGY

### ATOSIBAN

Solution for IV injection / Concentrate for solution for Infusion  
Vials 6.75 mg/0.9 ml, 37.5 mg/5 ml

STRAGEN Pharma engages in the development, registration, and supply of a selected range of oral, parenteral, and topical products in a variety of therapeutic areas, such as anti-infectives, cardiology, oncology, oral contraception, etc.

Generic and Generic+ drugs mainly focused on injectable anti-infective and oncology products, cardiology and gynaecology.



## GYNAECOLOGY

### CYPROTERONE ACETATE

Tablets 50 mg

### CYPROTERONE ACETATE / ETHINYLESTRADIOL

Tablets 2 mg/35 µg

### DESOGESTREL

Tablets 75 µg

### DESOGESTREL / ETHINYLESTRADIOL

Tablets 150 µg/30 µg, 150 µg/20 µg

### DIENOGEST

Tablets 2 mg

### DROSPIRENONE / ETHINYLESTRADIOL

Tablets 3 mg/0.03 mg

### GESTODENE / ETHINYLESTRADIOL

Tablets 75 µg/30 µg, 75 µg/20 µg, 60 µg/15 µg

### NOMEGESTROL ACETATE

Tablets 5 mg



A complete range of hormones

STRAGEN Pharma engages in the development, registration, and supply of a selected range of oral, parenteral, and topical products in a variety of therapeutic areas, such as anti-infectives, cardiology, oncology, oral contraception, etc.

Generic and Generic<sup>+</sup> drugs mainly focused on injectable anti-infective and oncology products, cardiology and gynaecology.



## ONCOLOGY

### **CYPROTERONE ACETATE**

Tablets 50 mg, 100 mg

### **OXALIPLATINE**

Powder for solution for infusion

Vials 50 mg/10 ml, 100 mg/20 ml

### **PACLITAXEL**

Concentrate for solution for infusion

Vials 30 mg/5 ml, 100 mg/16.7 ml, 300 mg/50 ml



## PHLEBOLOGY

### **DIOSMIN**

Tablets 600 mg

STRAGEN Pharma engages in the development, registration, and supply of a selected range of oral, parenteral, and topical products in a variety of therapeutic areas, such as anti-infectives, cardiology, oncology, oral contraception, etc.

Generic and Generic<sup>+</sup> drugs mainly focused on injectable anti-infective and oncology products, cardiology and gynaecology.



## HAEMATOLOGY

### **COAG. FACTOR VIIA (RECOMBINANT)**

Powder and solvent for solution for injection  
1.2 mg (60 KIU), 2.4 mg (120 KIU), 4.8 mg (240 KIU)

### **COAG. FACTOR VIII (RECOMBINANT)**

Powder and solvent for solution for injection  
250 IU, 500 IU, 1000 IU, 2000 IU

### **COAG. FACTOR IX (RECOMBINANT)**

Powder and solvent for solution for injection  
250 IU, 500 IU, 1000 IU



# CONSUMER HEALTH

STRAGEN Consumer Health specializes in the development of innovative products with clinically proven efficacy and safety.



**WOMEN** \_\_\_\_\_ 24  
STRAGEN offers a complete range of tailor-made solutions for each stage of women’s life supported by strong scientific evidence.



**INNOV** \_\_\_\_\_ 25  
STRAGEN Health Innov is made of 3 clinically proven solutions containing unique bioactives. These products offer innovative & natural alternatives in the high-potential segments such as allergic rhinitis, fatty liver disease and menopausal symptoms.



**SKIN** \_\_\_\_\_ 26  
STRAGEN offers an all-in-one & clinically proven solution for acne skin.



STRAGEN Consumer Health specializes in the development of innovative consumer health products with clinically proven efficacy and safety.

STRAGEN offers a complete range of tailor-made solutions for each stage of women's life supported by strong scientific evidence.

## WOMEN

**ENDELLIA** - ENDOMETRIOSIS MANAGEMENT

Patented botanical extract

COMING SOON

**GYNEVIA** - BACTERIAL VAGINOSIS TREATMENT

Patented  $\alpha$ -GOS & lactic acid

NEW

**ELLOVA** - FERTILITY ENHANCEMENT

Natural bioactives

COMING SOON

**IODACIF** - HEALTHY FETAL NEURAL DEVELOPMENT

Iodine, folic acid, B12 vitamin

NEW

**DIOSMIN 95<sup>®</sup>** - CHRONIC VENOUS INSUFFICIENCY

Diosmin 600 mg

**LURALEAN<sup>®</sup>** - APPETITE CONTROL

Glucomannan

**ESTROFREE-100<sup>®</sup>** - MENOPAUSE

Patented standardized blend of 3 botanical extracts

(*Cynanchum wilfordii*, *Phlomis umbrosa* and *Angelica gigas*)

Women's health is our concern



STRAGEN Consumer Health specializes in the development of innovative consumer health products with clinically proven efficacy and safety.

STRAGEN Health Innov is made of 3 clinically proven solutions containing unique bioactives. These products offer innovative & natural alternatives in high-potential segments.



## INNOV

### SNIZTOP®

THE NATURAL HISTAMINE BLOCKER FOR FAST ALLERGY RELIEF.

Proprietary formula made of natural & unique bioactives derived from quail eggs.



### LEVIKER®

THE NATURAL & INNOVATIVE SOLUTION FOR FATTY LIVER DISORDERS.

Proprietary standardized extract of Japanese apricot (*Prunus mume*).



### ESTROFREE-100®

THE NOVEL NON-ESTROGENIC & SAFE SOLUTION FOR MENOPAUSE.

Patented standardized blend of 3 botanical extracts (*Cynanchum wilfordii*, *Phlomis umbrosa* and *Angelica gigas*).



STRAGEN Consumer Health specializes in the development of innovative consumer health products with clinically proven efficacy and safety.

STRAGEN offers  
an all-in-one & clinically proven  
solution for acne skin.



## SKIN

### **TRIPLE EFFECT ACNE SERUM**

A UNIQUE & POWERFUL SOLUTION FOR ACNE SKIN.

Unique branded combination of natural actives.





# NEW DRUG DEVELOPMENT

STRAGEN New Drug Development identifies promising patented compounds from biotechnology start-ups as well as academic institutions and develops these into drugs of high therapeutic potential.



**ALX-009 - CYSTIC FIBROSIS** \_\_\_\_\_ 29

An innovative first-in-class orphan drug combination of two endogenous substances.



**STR-324 - PAIN** \_\_\_\_\_ 30

A first-in-class non-opioid painkiller with a safe, non-addictive, and innovative mode of action.



STRAGEN New Drug Development identifies promising patented compounds from biotechnology start-ups as well as academic institutions and develops these into drugs of high therapeutic potential.

STRAGEN New Drug Development designs and conducts the full development programme, from pre-clinical to manufacturing scale-up, paving the way to global registration.

### ALX-009 - CYSTIC FIBROSIS

ALX-009 is developed by the new biotechnology start-up Alaxia in which STRAGEN acquired a significant stake in 2011.

ALX-009 is an innovative first-in-class orphan drug combination of two endogenous substances administered by inhalation addressing a strong unmet medical need by targeting multi-drug-resistant (MDR) bacterial infections not treatable by current antibiotic therapies.

---

**2017-2018:** Phase I - First-in-Man clinical trials including Cystic Fibrosis patients. Evaluation of safety and tolerability of ALX-009 and its constituents.

**2019:** Start of Phase IIa - Proof of Concept in Cystic Fibrosis (MDR infections in adults).



STRAGEN New Drug Development identifies promising patented compounds from biotechnology start-ups as well as academic institutions and develops these into drugs of high therapeutic potential.

STRAGEN New Drug Development designs and conducts the full development programme, from pre-clinical to manufacturing scale-up, paving the way to global registration.

### STR-324 - PAIN

STR-324 is a first-in-class non-opioid painkiller with a safe, non-addictive, and innovative mode of action.

STR-324 is the synthetic equivalent of natural human peptides inhibiting the degradation of endogenous painkillers, showing efficacy on acute and prolonged pain without the common side effects of opioids (animal models).

---

**2018:** Phase I - First-in-Man clinical trials with injectable forms.

**2019:** Phase II - Proof of Concept in neuropathic pain.



STRAGEN,  
SWISS HEALTH CARE  
COMPANY



## STRAGEN FRANCE S.A.S.

Bâtiment Adénine  
60 avenue Rockefeller  
69008 Lyon - FRANCE  
tel +33 4 82 53 75 82  
fax +33 4 82 53 32 25  
info@stragenfrance.com  
www.stragen.com

## STRAGEN SERVICES

52 rue de la République  
69002 Lyon - FRANCE  
tel +33 4 78 42 95 26  
fax +33 4 78 42 55 71  
*Pharmacovigilance services:*  
pharmacovigilance@stragen.com  
*Clinical affairs services:*  
medaffairs@stragen.com  
www.stragen.ch/services



## STRAGEN UK Limited

Castle Court  
41 London Road  
Reigate  
Surrey RH2 9RJ - ENGLAND  
tel +44 173 773 5029  
info@stragenuk.com  
www.stragenuk.com



## STRAGEN PHARMA GmbH

TechnologiePark Köln  
Eupener Str. 135-137  
50933 Köln - DEUTSCHLAND  
tel +49-221-5716 4600  
fax +49-221-5716 4610  
info@stragen-pharma.de  
www.stragen.de



## STRAGEN NORDIC A/S

Helsingørsgade 8 C  
3400 Hillerød - DANMARK  
tel +45 48 10 88 10  
info@stragen.dk  
www.stragen.dk



## STRAGEN FINLAND OY

Regus Business Centre Graniitalo  
Jaakonkatu 3B, 7<sup>th</sup> floor  
00100 Helsinki - SUOMI  
tel +358 2 7360 078  
info@stragen.fi  
www.stragen.fi



## STRAGEN CANADA INC

Suite 1140  
3300 Bloor Street West  
11<sup>th</sup> Floor  
Centre Tower  
Toronto - Ontario - CANADA M8X 2X3  
tel 416 207 2072  
www.stragen.com



## STRAGEN FARMA S.A.

Alameda Santos 234  
9<sup>o</sup> andar  
Cerqueira Cesar  
São Paulo  
CEP 01418-000 - BRASIL  
tel +55 11 3372 50 50  
info@stragen.com  
www.stragen.com



## STRAGEN DAROU

4<sup>th</sup> floor  
N. 82,  
31<sup>st</sup> Ebne Sina St.  
Yousef Abad  
Zip code: 1433863596  
Tehran - IRAN  
tel +9821 88 72 80 85  
fax +9821 88 10 69 63  
info@stragendarou.com  
www.stragendarou.com



## STRAGEN PHARMA (THAILAND) Co. Ltd.

Floor 29  
Unit 29-56  
388 Exchange Tower  
Sukhumvit Road  
Klongtoey  
Bangkok 10110 - THAILAND  
www.stragen.com



## STRAGEN PHARMA SA VIETNAM

Saigon Centre  
F/4, Room No. 23  
65 Le Loi Street  
Ben Nghe Ward  
District 1  
Ho Chi Minh - VIETNAM  
tel +66 97 139 4194  
www.stragen.vn



STRAGEN,  
headquarters in Geneva,  
Switzerland



**STRAGEN PHARMA SA**

Chemin du Pré-Fleuri 3  
1228 Plan-les-Ouates / Geneva  
Switzerland  
tel +41 22 799 19 19  
fax +41 22 799 19 99  
info@stragen.ch  
www.stragen.com

WWW.STRAGEN.CH

CORP\_CPH\_MAIL\_1117\_02